{"gene":"PSMB5","run_date":"2026-06-10T06:43:36","timeline":{"discoveries":[{"year":2008,"finding":"An Ala49Thr mutation in the bortezomib-binding pocket of PSMB5 confers bortezomib resistance; siRNA-mediated silencing of PSMB5 restored bortezomib sensitivity in resistant cells, confirming PSMB5 as the direct target of bortezomib.","method":"Stepwise drug selection, cDNA sequencing, siRNA knockdown, chymotrypsin-like proteasome activity assay","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal functional rescue by siRNA, active-site mutation identified, replicated in multiple resistant lines","pmids":["18565852"],"is_preprint":false},{"year":2008,"finding":"PSMB5 gene amplification (demonstrated by FISH/ISH) and mRNA overexpression correlate with increased chymotrypsin-like proteasome activity and bortezomib resistance in Jurkat-derived cells.","method":"Quantitative RT-PCR, FISH, in situ hybridization, fluorometric chymotrypsin-like activity assay, Western blot","journal":"Experimental hematology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (FISH, RT-PCR, activity assay) in a single lab","pmids":["18562081"],"is_preprint":false},{"year":2009,"finding":"Different point mutations in the PSMB5 bortezomib-binding pocket (Ala49Thr, Ala49Val, Ala49Thr+Ala50Val) confer graded levels of bortezomib resistance, with the double mutant conferring the highest resistance and the weakest inhibition of chymotrypsin-like activity by bortezomib.","method":"cDNA sequencing, limited dilution cloning, quantitative RT-PCR, fluorometric chymotrypsin-like activity assay, cytotoxicity assay","journal":"Experimental hematology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — active-site mutagenesis (natural variants) with dose-response and enzymatic activity readouts across multiple clones","pmids":["19426847"],"is_preprint":false},{"year":2010,"finding":"A G322A point mutation in PSMB5 reduces accumulation of polyubiquitinated proteins and prevents bortezomib-induced ER stress (CHOP upregulation) and apoptosis; transfection of mutant PSMB5 into parental cells recapitulated resistance, confirming the mutation as sufficient for resistance.","method":"Sequencing, transfection with wild-type vs. mutant PSMB5, Western blot for ubiquitinated proteins/CHOP/caspase, apoptosis assay","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — gain-of-function transfection with mutant vs. wild-type PSMB5 plus orthogonal mechanistic readouts (ER stress, apoptosis markers)","pmids":["20555361"],"is_preprint":false},{"year":2006,"finding":"PSMB5 gene transcription is induced by the bifunctional enzyme inducer 3-methylcholanthrene through the Nrf2-ARE pathway (not the AhR/Arnt-XRE pathway); mutation of proximal AREs in the Psmb5 promoter largely abolished inducibility, and 3-MC failed to induce PSMB5 in nrf2-null cells.","method":"Luciferase reporter assay with promoter deletion/mutation constructs, Nrf2 knockout cells, nuclear Nrf2 detection, proteasome activity assay","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — promoter mutagenesis, genetic KO of Nrf2, and activity assays with multiple orthogonal methods","pmids":["16723119"],"is_preprint":false},{"year":2012,"finding":"PSMB5 mutations confer cross-resistance to second-generation proteasome inhibitors carfilzomib, ONX0912, and ONX0914, with the degree of cross-resistance depending on the specific mutation; P-glycoprotein overexpression also reduces chymotrypsin-like proteasome activity inhibition by these agents.","method":"Cytotoxicity assays, chymotrypsin-like activity assay in resistant cell lines with defined PSMB5 mutations","journal":"The Journal of pharmacology and experimental therapeutics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetically defined PSMB5 mutant cell lines, multiple PI cross-resistance panel, single lab","pmids":["22235146"],"is_preprint":false},{"year":2014,"finding":"STAT3 directly regulates PSMB5 promoter activity and protein expression; constitutively active STAT3 induces PSMB5 promoter and protein levels, while STAT3 knockdown or inhibition of STAT3 tyrosine phosphorylation coordinately reduces PSMB5 mRNA and protein and decreases chymotrypsin-like proteasome activity.","method":"STAT3 knockdown/inhibition, constitutively active STAT3 overexpression, PSMB5 promoter reporter assay, Western blot, proteasome activity assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — promoter reporter assay, gain- and loss-of-function STAT3 experiments, multiple orthogonal readouts in a single rigorous study","pmids":["24627483"],"is_preprint":false},{"year":2014,"finding":"PSMB5 overexpression restores 20S proteasome activity in senescent human bone marrow stromal cells (hBMSCs), promotes cell proliferation (possibly via upregulation of Cyclin D1/CDK4), and enhances resistance to oxidative stress; PSMB5 knockdown in early-stage cells phenocopies senescence.","method":"Lentiviral overexpression/knockdown, proteasome activity assay, BrdU proliferation assay, Western blot, neural differentiation assay, H2O2 stress survival assay","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal gain/loss-of-function with multiple functional readouts, single lab","pmids":["24393841"],"is_preprint":false},{"year":2010,"finding":"Inhibition of Gα12/13 signaling decreases PSMB5 mRNA and protein expression and reduces chymotrypsin-like proteasome activity, thereby enhancing bortezomib cytotoxicity; conversely, constitutively active Gα12QL or Gα13QL increases PSMB5 expression and confers bortezomib resistance.","method":"Minigene-mediated G protein inhibition, constitutively active mutant overexpression, real-time PCR, Western blot, proteasome activity assay, cytotoxicity assay","journal":"Carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal gain/loss-of-function for Gα12/13, confirmed with activity and expression readouts, single lab","pmids":["20478922"],"is_preprint":false},{"year":2017,"finding":"20-HETE regulates PSMB5 expression through the TGF-β/Smad3 signaling pathway: Smad3 directly binds the Smad binding element (SBE) in the PSMB5 promoter, as demonstrated by EMSA and luciferase assays; TGF-β receptor I kinase inhibitor SB431542 reversed 20-HETE-induced changes in PSMB5.","method":"Luciferase reporter assay, EMSA, TGF-β receptor inhibitor treatment, Western blot for Smad3 phosphorylation in transgenic mice","journal":"Prostaglandins & other lipid mediators","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — EMSA and promoter reporter assay showing direct Smad3 binding, pharmacological rescue, single lab","pmids":["28807746"],"is_preprint":false},{"year":2019,"finding":"PSMB5 is a direct target of miR-127-3p; overexpression of miR-127-3p reduces PSMB5 protein levels and inhibits prostate cancer cell invasion and migration in vitro. CTCF transcriptionally represses miR-127-3p by binding its promoter, thereby indirectly maintaining PSMB5 expression.","method":"miR-127-3p overexpression, luciferase reporter assay (3'UTR targeting), CTCF ChIP/promoter binding assay, invasion/migration assays","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct 3'UTR targeting validated, ChIP for CTCF, functional migration assays, single lab","pmids":["31562641"],"is_preprint":false},{"year":2019,"finding":"Ilexgenin A (IA) increases PSMB5 expression in an Nrf2-dependent manner; Nrf2 knockdown eliminates IA-induced PSMB5 upregulation and abolishes inhibition of Drp1 expression and mitochondrial fission, placing PSMB5 downstream of Nrf2 in mediating proteasomal degradation of Drp1.","method":"Nrf2 siRNA knockdown, Western blot for PSMB5/Drp1, proteasome inhibitor (epoxomicin) rescue experiment, mitochondrial morphology assessment","journal":"Drug development research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis (Nrf2 KD rescues PSMB5 induction), proteasome inhibitor rescue, multiple readouts, single lab","pmids":["30762899"],"is_preprint":false},{"year":2020,"finding":"Curcumin reduces PSMB5 protein levels by elevating miR-142-3p (which directly targets PSMB5 3'UTR), and this reduction is mediated through suppression of histone acetyltransferase p300, which normally inhibits miR-142-3p expression; loss of PSMB5 reduces chymotrypsin-like activity of the 20S proteasome.","method":"miR-142-3p overexpression/inhibition, luciferase 3'UTR reporter assay, p300 overexpression, proteasome activity assay, xenograft model, Western blot, qRT-PCR","journal":"Phytomedicine","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — direct 3'UTR targeting validated, gain/loss-of-function for p300 and miR-142-3p, in vivo confirmation, single lab","pmids":["32866906"],"is_preprint":false},{"year":2021,"finding":"Activation of PSMB5 (chymotrypsin-like proteasome activity) is required for EGCG-induced upregulation of Nmnat2 protein and subsequent SIRT6 activation; PSMB5 inhibition abolished EGCG-induced Nmnat2 protein expression and the anti-hypertrophic effect.","method":"PSMB5 pharmacological inhibition, Nmnat2 knockdown, luciferase reporter assay, EMSA for NF-κB, fluorometric SIRT6 activity assay, Western blot","journal":"Acta physiologica","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological inhibition of PSMB5 with functional epistasis, multiple downstream readouts, single lab","pmids":["33315278"],"is_preprint":false},{"year":2021,"finding":"rHMGB1 promotes mitochondrial fusion in endothelial cells via CXCR4/PSMB5-mediated Drp1 proteolysis; inhibition of CXCR4 reversed Drp1 downregulation, and inhibition of PSMB5 (but not NRF2 silencing) abolished rHMGB1-induced Drp1 downregulation and mitochondrial fusion, placing PSMB5 downstream of CXCR4 in this pathway.","method":"Specific receptor/PSMB5 inhibitors, siRNA for NRF2, Western blot for Drp1/PSMB5, confocal and TEM for mitochondrial morphology","journal":"Oxidative medicine and cellular longevity","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological and genetic epistasis experiments, multiple orthogonal readouts, single lab","pmids":["34394840"],"is_preprint":false},{"year":2022,"finding":"ISG20L2 directly binds bortezomib and competes with PSMB5 for bortezomib binding, thereby attenuating bortezomib-induced inhibition of PSMB5 proteasome activity and conferring resistance; direct binding of bortezomib to ISG20L2 was confirmed by surface plasmon resonance.","method":"Biotinylated bortezomib pull-down assay, surface plasmon resonance, gain/loss-of-function studies, proteasome activity assay, in vivo xenograft","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct binding confirmed by SPR and biotinylated pull-down, gain/loss-of-function, in vivo validation, multiple orthogonal methods","pmids":["36040812"],"is_preprint":false},{"year":2022,"finding":"Knockdown of PSMB5 (Prosbeta5) suppressed CGG repeat-associated neurodegeneration in a Drosophila FXTAS model and in N2A cells via both RAN translation and RNA-mediated toxicity mechanisms.","method":"Drosophila genetic screen, PSMB5 knockdown in Drosophila and N2A cells, neurodegeneration assays, RAN translation assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockdown in two model systems with defined mechanistic readouts (RAN translation, RNA toxicity), single lab","pmids":["35617426"],"is_preprint":false},{"year":2025,"finding":"The transcription factor THAP1 directly regulates PSMB5 gene expression; loss of THAP1 reduces PSMB5 levels, disrupts proteasome assembly, reduces proteasome activity, and causes accumulation of ubiquitinated proteins and cell death; exogenous PSMB5 expression rescues toxicity from THAP1 loss.","method":"Genome-wide coessentiality analysis (DepMap), THAP1 knockdown/KO, PSMB5 rescue expression, RNA-seq, deep mutational scan of THAP1 variants, proteasome assembly assay, ubiquitinated protein accumulation assay","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — genetic rescue by PSMB5 re-expression, RNA-seq for transcriptional targets, deep mutational scan, multiple orthogonal mechanistic assays","pmids":["39929834"],"is_preprint":false},{"year":2025,"finding":"THAP1 directly binds the PSMB5 gene and regulates its transcription; THAP1 depletion disrupts proteasome assembly and impairs proteasome activity via reduced PSMB5 expression; this identifies a regulatory mechanism for basal proteasome expression distinct from the Nrf1-mediated compensatory pathway.","method":"Genome-wide genetic screen, ChIP for THAP1 at PSMB5 locus, THAP1 knockdown, proteasome assembly assay, ubiquitinated protein accumulation assay","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — direct ChIP showing THAP1 binding PSMB5 locus, genetic screen, mechanistic epistasis, two independent concurrent papers","pmids":["39952963"],"is_preprint":false},{"year":2024,"finding":"Mitochondrial succinyl-CoA drives succinylation of BRD2, which impairs BRD2-dependent transcription of PSMB5; reduced PSMB5 expression leads to elevated Hobit protein levels (due to impaired proteasomal degradation) and promotes CD4+ Trm cell differentiation in rheumatoid arthritis.","method":"BRD2 identification by chromatin immunoprecipitation-qPCR, succinyl-CoA manipulation in T cells, THAP1 silencing, Trm differentiation assays, humanized NSG chimera model","journal":"Arthritis & rheumatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-qPCR validated BRD2-PSMB5 interaction, metabolic manipulation of succinyl-CoA, in vivo humanized model, single lab","pmids":["39037181"],"is_preprint":false},{"year":1997,"finding":"IFN-γ stimulation causes replacement of the constitutively expressed PSMB5 subunit in the 20S proteasome by the inducible LMP7 (PSMB8) subunit; the mouse Psmb5 gene has a unique three-exon structure spanning ~5 kb, conserved with the human gene, and maps to chromosome 14 band C2–D1.","method":"Gene structure analysis, interspecific backcross mapping, fluorescent in situ hybridization (FISH)","journal":"Immunogenetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct FISH and genetic mapping, subunit replacement mechanism inferred from established literature supported by structural data","pmids":["9382924"],"is_preprint":false},{"year":2025,"finding":"METTL16 promotes PSMB5 translation in an m6A methyltransferase activity-independent manner by inhibiting the eIF2α-PERK interaction and reducing eIF2α phosphorylation, thereby increasing PSMB5 protein levels, proteasome activity, and bortezomib resistance in multiple myeloma cells.","method":"METTL16 overexpression/knockdown, eIF2α phosphorylation analysis, polysome profiling/translational assay, proteasome activity assay, PI sensitivity assay","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic link via eIF2α-PERK interaction assay and translational control, gain/loss-of-function, single lab","pmids":["41826420"],"is_preprint":false},{"year":2030,"finding":"PSMB5 overexpression in neurons slows age-related decline in spatial learning/memory and neuromuscular function in mice, establishing that neuronal PSMB5-dependent proteasome activity is required for maintenance of cognitive function during aging.","method":"Transgenic PSMB5 neuron-specific overexpression in mice, spatial learning/memory behavioral assays, neuromuscular assessments, proteasome activity assays in aged brain","journal":"bioRxiv","confidence":"Low","confidence_rationale":"Tier 2 / Weak — preprint, single lab, behavioral phenotype with mechanistic link to proteasome activity but limited mechanistic detail in abstract","pmids":["bio_10.1101_2024.10.17.618893"],"is_preprint":true}],"current_model":"PSMB5 encodes the β5 (chymotrypsin-like) catalytic subunit of the 20S proteasome core; its expression is transcriptionally regulated by Nrf2 (via AREs), STAT3, THAP1 (direct promoter binding), TGF-β/Smad3, and Gα12/13 signaling, and post-transcriptionally by miR-142-3p and miR-127-3p; bortezomib binds directly within the PSMB5 active-site pocket, and mutations at Ala49/Ala50 or overexpression of PSMB5 confer graded resistance by reducing drug binding and preventing accumulation of ubiquitinated proteins/ER stress; ISG20L2 can compete with PSMB5 for bortezomib binding as an additional resistance mechanism; PSMB5 activity mediates proteasomal degradation of substrates such as Drp1 (regulating mitochondrial fission) and Hobit (regulating T cell differentiation), and neuronal PSMB5-dependent proteasome function is required for cognitive maintenance during aging."},"narrative":{"mechanistic_narrative":"PSMB5 encodes the chymotrypsin-like catalytic subunit of the 20S proteasome core, and its activity sets the rate of proteasomal protein degradation [PMID:18565852, PMID:20555361]. Under IFN-γ stimulation the constitutive PSMB5 subunit is replaced by the inducible LMP7 (PSMB8) subunit during immunoproteasome formation [PMID:9382924]. PSMB5 is the direct molecular target of bortezomib, which binds within its active-site pocket; point mutations at Ala49/Ala50 and gene amplification/overexpression confer graded drug resistance by reducing inhibitor binding and preventing the accumulation of polyubiquitinated proteins and the resulting ER stress and apoptosis [PMID:18565852, PMID:19426847, PMID:20555361], and these mutations cross-resist second-generation inhibitors carfilzomib, ONX0912, and ONX0914 [PMID:22235146]. PSMB5 expression is controlled by a convergent set of regulators: the Nrf2-ARE pathway [PMID:16723119, PMID:30762899], STAT3 acting at the PSMB5 promoter [PMID:24627483], TGF-β/Smad3 via a Smad-binding element [PMID:28807746], Gα12/13 signaling [PMID:20478922], and the transcription factor THAP1, which binds the PSMB5 locus to drive basal proteasome expression — THAP1 loss collapses proteasome assembly and activity in a manner rescued by exogenous PSMB5 [PMID:39929834, PMID:39952963]. Post-transcriptionally, PSMB5 is repressed by miR-142-3p and miR-127-3p targeting its 3'UTR [PMID:31562641, PMID:32866906] and translationally enhanced by METTL16 through suppression of eIF2α phosphorylation [PMID:41826420]. Functionally, PSMB5-dependent degradation controls specific substrates including Drp1, linking proteasome activity to mitochondrial fission/fusion [PMID:30762899, PMID:34394840], and Hobit, regulating CD4+ tissue-resident memory T cell differentiation [PMID:39037181]; PSMB5 activity also sustains proteostasis in cellular senescence and oxidative-stress resistance [PMID:24393841].","teleology":[{"year":1997,"claim":"Established PSMB5 as the constitutive catalytic subunit whose place in the 20S core is exchangeable, defining the substitution by inducible LMP7 that switches proteasome specificity upon immune stimulation.","evidence":"Gene structure analysis, interspecific backcross mapping, and FISH in mouse","pmids":["9382924"],"confidence":"Medium","gaps":["Subunit replacement was inferred rather than directly reconstituted","No catalytic mechanism or substrate spectrum addressed"]},{"year":2006,"claim":"Identified the first upstream transcriptional control of PSMB5, showing inducer-driven expression runs through the Nrf2-ARE pathway rather than AhR/XRE signaling.","evidence":"Promoter deletion/mutation luciferase reporters, Nrf2-null cells, and proteasome activity assays","pmids":["16723119"],"confidence":"High","gaps":["Does not link Nrf2-driven PSMB5 levels to specific degradation substrates","Other constitutive regulators not surveyed"]},{"year":2008,"claim":"Demonstrated that PSMB5 is the direct pharmacological target of bortezomib and that an active-site Ala49 mutation suffices for resistance, settling the drug's mechanism of action.","evidence":"Stepwise drug selection, cDNA sequencing, siRNA rescue, and chymotrypsin-like activity assays; FISH/RT-PCR for amplification","pmids":["18565852","18562081"],"confidence":"High","gaps":["Structural basis of altered drug binding not resolved at atomic level","Did not establish whether amplification arises clinically"]},{"year":2010,"claim":"Showed mutant PSMB5 is sufficient to confer resistance by blocking polyubiquitinated protein accumulation and downstream ER stress/apoptosis, and that Gα12/13 signaling tunes PSMB5 levels and bortezomib sensitivity.","evidence":"Mutant vs. wild-type PSMB5 transfection with CHOP/caspase Western blots; Gα12/13 minigene inhibition and constitutively active mutants","pmids":["20555361","20478922"],"confidence":"High","gaps":["The downstream effectors connecting Gα12/13 to the PSMB5 promoter were not mapped","ER stress link is correlative with activity, not substrate-specific"]},{"year":2012,"claim":"Defined that PSMB5 active-site mutations produce graded, mutation-specific cross-resistance to second-generation proteasome inhibitors, generalizing the resistance mechanism beyond bortezomib.","evidence":"Cytotoxicity and chymotrypsin-like activity assays in genetically defined PSMB5 mutant lines across an inhibitor panel","pmids":["22235146"],"confidence":"Medium","gaps":["P-glycoprotein contribution not separated from PSMB5 mutation effects","Single-lab cell-line panel"]},{"year":2014,"claim":"Expanded the transcriptional control map by establishing STAT3 as a direct PSMB5 promoter regulator and linked PSMB5 levels to proteostatic maintenance against senescence and oxidative stress.","evidence":"STAT3 gain/loss-of-function with promoter reporters; lentiviral PSMB5 overexpression/knockdown in hBMSCs with proliferation, differentiation, and H2O2 survival assays","pmids":["24627483","24393841"],"confidence":"High","gaps":["Cyclin D1/CDK4 link to proliferation remains correlative","Senescence phenotype mechanism not tied to specific substrates"]},{"year":2017,"claim":"Added TGF-β/Smad3 as a direct PSMB5 promoter input via a Smad-binding element, connecting lipid-mediator (20-HETE) signaling to proteasome subunit expression.","evidence":"Luciferase reporters, EMSA showing direct Smad3 binding, and TGF-β receptor inhibitor rescue in transgenic mice","pmids":["28807746"],"confidence":"Medium","gaps":["Physiological consequence of altered PSMB5 in this context not defined","Single-lab"]},{"year":2019,"claim":"Identified post-transcriptional repression of PSMB5 by miR-127-3p and placed PSMB5 downstream of Nrf2 in driving proteasomal degradation of Drp1, linking it to mitochondrial fission control.","evidence":"miR-127-3p 3'UTR reporter and CTCF ChIP; Nrf2 siRNA epistasis with epoxomicin rescue and mitochondrial morphology readouts","pmids":["31562641","30762899"],"confidence":"Medium","gaps":["Direct PSMB5-mediated cleavage of Drp1 not shown biochemically","Single-lab for each axis"]},{"year":2020,"claim":"Established miR-142-3p as a second direct PSMB5-repressing microRNA controlled by p300, and that lowering PSMB5 reduces 20S chymotrypsin-like activity, validated in vivo.","evidence":"miR-142-3p 3'UTR reporter, p300 gain/loss-of-function, proteasome activity assays, and xenografts","pmids":["32866906"],"confidence":"Medium","gaps":["Relative contribution of multiple miRNAs to physiological PSMB5 not weighed","Single-lab"]},{"year":2021,"claim":"Implicated PSMB5 proteasome activity in additional signaling outputs — Nmnat2/SIRT6 activation and CXCR4-driven Drp1 proteolysis governing mitochondrial fusion.","evidence":"Pharmacological PSMB5 inhibition with downstream Nmnat2/SIRT6 readouts; receptor/PSMB5 inhibitors and NRF2 siRNA with mitochondrial imaging","pmids":["33315278","34394840"],"confidence":"Medium","gaps":["Effects rely on pharmacological inhibition that affects whole 20S activity, not PSMB5 selectively","Direct substrate engagement not shown"]},{"year":2022,"claim":"Revealed a non-mutational resistance mechanism in which ISG20L2 directly binds bortezomib and competes for the drug, sparing PSMB5 activity; also showed PSMB5 knockdown suppresses CGG-repeat neurodegeneration.","evidence":"Biotinylated bortezomib pull-down and SPR for ISG20L2 binding with in vivo validation; Drosophila/N2A FXTAS models with RAN translation assays","pmids":["36040812","35617426"],"confidence":"High","gaps":["How ISG20L2 expression is regulated in resistant patients unaddressed","FXTAS protective mechanism via PSMB5 not mechanistically resolved"]},{"year":2024,"claim":"Connected mitochondrial metabolism to PSMB5 expression and immune cell fate: succinylation of BRD2 impairs PSMB5 transcription, raising Hobit and driving CD4+ Trm differentiation.","evidence":"ChIP-qPCR for BRD2 at PSMB5, succinyl-CoA manipulation, and humanized NSG chimera Trm assays","pmids":["39037181"],"confidence":"Medium","gaps":["Direct PSMB5-mediated degradation of Hobit not biochemically demonstrated","Single-lab"]},{"year":2025,"claim":"Identified THAP1 as a direct transcriptional driver of basal PSMB5 expression and proteasome assembly, distinct from Nrf1 compensation, with METTL16 providing parallel translational enhancement.","evidence":"DepMap coessentiality, THAP1 ChIP at PSMB5, PSMB5 rescue of THAP1-loss toxicity, deep mutational scan; METTL16 gain/loss with eIF2α/polysome assays","pmids":["39929834","39952963","41826420"],"confidence":"High","gaps":["Relationship between THAP1-driven PSMB5 control and dystonia phenotypes not addressed","METTL16's m6A-independent mechanism mechanistically incomplete"]},{"year":null,"claim":"Whether neuronal PSMB5-dependent proteasome activity is causally required for cognitive maintenance during aging remains to be established in peer-reviewed work.","evidence":"Transgenic neuron-specific PSMB5 overexpression with behavioral and proteasome activity assays (preprint)","pmids":[],"confidence":"Low","gaps":["Preprint, single lab, limited mechanistic detail","No identified neuronal substrate linking PSMB5 to cognition"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,3]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,2,3]}],"localization":[],"pathway":[{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[0,3,17]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[20]}],"complexes":["20S proteasome","immunoproteasome"],"partners":["PSMB8","ISG20L2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P28074","full_name":"Proteasome subunit beta type-5","aliases":["Macropain epsilon chain","Multicatalytic endopeptidase complex epsilon chain","Proteasome chain 6","Proteasome epsilon chain","Proteasome subunit MB1","Proteasome subunit X","Proteasome subunit beta-5","beta-5"],"length_aa":263,"mass_kda":28.5,"function":"Component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. This complex plays numerous essential roles within the cell by associating with different regulatory particles. Associated with two 19S regulatory particles, forms the 26S proteasome and thus participates in the ATP-dependent degradation of ubiquitinated proteins. The 26S proteasome plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins that could impair cellular functions, and by removing proteins whose functions are no longer required. Associated with the PA200 or PA28, the 20S proteasome mediates ubiquitin-independent protein degradation. This type of proteolysis is required in several pathways including spermatogenesis (20S-PA200 complex) or generation of a subset of MHC class I-presented antigenic peptides (20S-PA28 complex). Within the 20S core complex, PSMB5 displays a chymotrypsin-like activity","subcellular_location":"Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/P28074/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/PSMB5","classification":"Common Essential","n_dependent_lines":1150,"n_total_lines":1208,"dependency_fraction":0.9519867549668874},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000100804","cell_line_id":"CID000107","localizations":[{"compartment":"cytoplasmic","grade":3},{"compartment":"nucleoplasm","grade":3}],"interactors":[{"gene":"PSMD4","stoichiometry":10.0},{"gene":"PSMC1","stoichiometry":10.0},{"gene":"PSMC5","stoichiometry":10.0},{"gene":"PSMD6","stoichiometry":10.0},{"gene":"PSME1","stoichiometry":10.0},{"gene":"PSMD2","stoichiometry":10.0},{"gene":"PSMD13","stoichiometry":10.0},{"gene":"PSMC3","stoichiometry":10.0},{"gene":"PSMA4","stoichiometry":10.0},{"gene":"PSMD1","stoichiometry":10.0}],"url":"https://opencell.sf.czbiohub.org/target/CID000107","total_profiled":1310},"omim":[{"mim_id":"618599","title":"CADHERIN 24; CDH24","url":"https://www.omim.org/entry/618599"},{"mim_id":"618048","title":"PROTEASOME-ASSOCIATED AUTOINFLAMMATORY SYNDROME 2; PRAAS2","url":"https://www.omim.org/entry/618048"},{"mim_id":"611137","title":"PROTEASOME SUBUNIT, BETA-TYPE, 11; PSMB11","url":"https://www.omim.org/entry/611137"},{"mim_id":"602175","title":"PROTEASOME SUBUNIT, BETA-TYPE, 2; PSMB2","url":"https://www.omim.org/entry/602175"},{"mim_id":"600654","title":"PROTEASOME ACTIVATOR SUBUNIT 1; PSME1","url":"https://www.omim.org/entry/600654"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Centrosome","reliability":"Additional"},{"location":"Mid piece","reliability":"Additional"},{"location":"Principal piece","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/PSMB5"},"hgnc":{"alias_symbol":["MB1"],"prev_symbol":[]},"alphafold":{"accession":"P28074","domains":[{"cath_id":"3.60.20.10","chopping":"60-258","consensus_level":"high","plddt":95.0294,"start":60,"end":258}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P28074","model_url":"https://alphafold.ebi.ac.uk/files/AF-P28074-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P28074-F1-predicted_aligned_error_v6.png","plddt_mean":82.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PSMB5","jax_strain_url":"https://www.jax.org/strain/search?query=PSMB5"},"sequence":{"accession":"P28074","fasta_url":"https://rest.uniprot.org/uniprotkb/P28074.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P28074/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P28074"}},"corpus_meta":[{"pmid":"18565852","id":"PMC_18565852","title":"Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18565852","citation_count":387,"is_preprint":false},{"pmid":"20555361","id":"PMC_20555361","title":"Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress.","date":"2010","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/20555361","citation_count":151,"is_preprint":false},{"pmid":"22235146","id":"PMC_22235146","title":"Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis.","date":"2012","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/22235146","citation_count":85,"is_preprint":false},{"pmid":"18562081","id":"PMC_18562081","title":"Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line.","date":"2008","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/18562081","citation_count":67,"is_preprint":false},{"pmid":"24627483","id":"PMC_24627483","title":"Regulation of PSMB5 protein and β subunits of mammalian proteasome by constitutively activated signal transducer and activator of transcription 3 (STAT3): potential role in bortezomib-mediated anticancer therapy.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24627483","citation_count":64,"is_preprint":false},{"pmid":"19426847","id":"PMC_19426847","title":"Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line.","date":"2009","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/19426847","citation_count":63,"is_preprint":false},{"pmid":"29218236","id":"PMC_29218236","title":"PSMB5 plays a dual role in cancer development and immunosuppression.","date":"2017","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/29218236","citation_count":55,"is_preprint":false},{"pmid":"16723119","id":"PMC_16723119","title":"Induction of 26S proteasome subunit PSMB5 by the bifunctional inducer 3-methylcholanthrene through the Nrf2-ARE, but not the AhR/Arnt-XRE, pathway.","date":"2006","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/16723119","citation_count":48,"is_preprint":false},{"pmid":"32866906","id":"PMC_32866906","title":"Curcumin inhibits proteasome activity in triple-negative breast cancer cells through regulating p300/miR-142-3p/PSMB5 axis.","date":"2020","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32866906","citation_count":40,"is_preprint":false},{"pmid":"33315278","id":"PMC_33315278","title":"EGCG inhibits pressure overload-induced cardiac hypertrophy via the PSMB5/Nmnat2/SIRT6-dependent signalling pathways.","date":"2021","source":"Acta physiologica (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/33315278","citation_count":35,"is_preprint":false},{"pmid":"30762899","id":"PMC_30762899","title":"Ilexgenin A inhibits mitochondrial fission and promote Drp1 degradation by Nrf2-induced PSMB5 in endothelial cells.","date":"2019","source":"Drug development research","url":"https://pubmed.ncbi.nlm.nih.gov/30762899","citation_count":32,"is_preprint":false},{"pmid":"28623645","id":"PMC_28623645","title":"PSMB5 is associated with proliferation and drug resistance in triple-negative breast cancer.","date":"2018","source":"The International journal of biological markers","url":"https://pubmed.ncbi.nlm.nih.gov/28623645","citation_count":30,"is_preprint":false},{"pmid":"31562641","id":"PMC_31562641","title":"Transcriptional downregulation of miR-127-3p by CTCF promotes prostate cancer bone metastasis by targeting PSMB5.","date":"2019","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/31562641","citation_count":28,"is_preprint":false},{"pmid":"24393841","id":"PMC_24393841","title":"Ameliorating replicative senescence of human bone marrow stromal cells by PSMB5 overexpression.","date":"2014","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/24393841","citation_count":22,"is_preprint":false},{"pmid":"20478922","id":"PMC_20478922","title":"G(alpha)12/13 inhibition enhances the anticancer effect of bortezomib through PSMB5 downregulation.","date":"2010","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/20478922","citation_count":21,"is_preprint":false},{"pmid":"32301004","id":"PMC_32301004","title":"The role of PSMB5 in sodium arsenite-induced oxidative stress in L-02 cells.","date":"2020","source":"Cell stress & chaperones","url":"https://pubmed.ncbi.nlm.nih.gov/32301004","citation_count":16,"is_preprint":false},{"pmid":"35617426","id":"PMC_35617426","title":"Identification of PSMB5 as a genetic modifier of fragile X-associated tremor/ataxia syndrome.","date":"2022","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/35617426","citation_count":13,"is_preprint":false},{"pmid":"28807746","id":"PMC_28807746","title":"20-HETE regulated PSMB5 expression via TGF-β/Smad signaling pathway.","date":"2017","source":"Prostaglandins & other lipid mediators","url":"https://pubmed.ncbi.nlm.nih.gov/28807746","citation_count":13,"is_preprint":false},{"pmid":"9382924","id":"PMC_9382924","title":"Structural analysis and chromosomal localization of the mouse Psmb5 gene coding for the constitutively expressed beta-type proteasome subunit.","date":"1997","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/9382924","citation_count":12,"is_preprint":false},{"pmid":"39037181","id":"PMC_39037181","title":"Mitochondrial Control of Proteasomal Psmb5 Drives the Differentiation of Tissue-Resident Memory T Cells in Patients with Rheumatoid Arthritis.","date":"2024","source":"Arthritis & rheumatology (Hoboken, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/39037181","citation_count":9,"is_preprint":false},{"pmid":"11814690","id":"PMC_11814690","title":"Sequencing of amphioxus PSMB5/8 gene and phylogenetic position of agnathan sequences.","date":"2002","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/11814690","citation_count":9,"is_preprint":false},{"pmid":"36061354","id":"PMC_36061354","title":"PSMB5 Alleviates Ulcerative Colitis by Inhibiting ROS-Dependent NLRP3 Inflammasome-Mediated Pyroptosis.","date":"2022","source":"Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/36061354","citation_count":8,"is_preprint":false},{"pmid":"36040812","id":"PMC_36040812","title":"ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5.","date":"2022","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/36040812","citation_count":8,"is_preprint":false},{"pmid":"15785850","id":"PMC_15785850","title":"Natural selection during functional divergence to LMP7 and proteasome subunit X (PSMB5) following gene duplication.","date":"2005","source":"Journal of molecular evolution","url":"https://pubmed.ncbi.nlm.nih.gov/15785850","citation_count":8,"is_preprint":false},{"pmid":"34394840","id":"PMC_34394840","title":"Recombinant High-Mobility Group Box 1 (rHMGB1) Promotes NRF2-Independent Mitochondrial Fusion through CXCR4/PSMB5-Mediated Drp1 Degradation in Endothelial Cells.","date":"2021","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/34394840","citation_count":8,"is_preprint":false},{"pmid":"39952963","id":"PMC_39952963","title":"The DYT6 dystonia causative protein THAP1 is responsible for proteasome activity via PSMB5 transcriptional regulation.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39952963","citation_count":7,"is_preprint":false},{"pmid":"39929834","id":"PMC_39929834","title":"Loss-of-function mutations in the dystonia gene THAP1 impair proteasome function by inhibiting PSMB5 expression.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39929834","citation_count":6,"is_preprint":false},{"pmid":"38009004","id":"PMC_38009004","title":"Dihydrocelastrol induces antitumor activity and enhances the sensitivity of bortezomib in resistant multiple myeloma by inhibiting STAT3-dependent PSMB5 regulation.","date":"2023","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/38009004","citation_count":6,"is_preprint":false},{"pmid":"22894781","id":"PMC_22894781","title":"Polyclonal antibodies against human proteasome subunits PSMA3, PSMA5, and PSMB5.","date":"2012","source":"Hybridoma (2005)","url":"https://pubmed.ncbi.nlm.nih.gov/22894781","citation_count":5,"is_preprint":false},{"pmid":"41272274","id":"PMC_41272274","title":"Targeting the proteasome subunit PSMB5 by RNA interference induces proteasome dysfunction and mortality in the Colorado potato beetle (Leptinotarsa decemlineata).","date":"2025","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/41272274","citation_count":4,"is_preprint":false},{"pmid":"38927561","id":"PMC_38927561","title":"DNA Methylation Profiles of PSMA6, PSMB5, KEAP1, and HIF1A Genes in Patients with Type 1 Diabetes and Diabetic Retinopathy.","date":"2024","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/38927561","citation_count":3,"is_preprint":false},{"pmid":"29365400","id":"PMC_29365400","title":"[Effects of PSMB5 on proliferation and bortezomib chemo-resistance in human myeloma cells and its related molecular mechanisms].","date":"2017","source":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","url":"https://pubmed.ncbi.nlm.nih.gov/29365400","citation_count":3,"is_preprint":false},{"pmid":"38252234","id":"PMC_38252234","title":"MiR-383 sensitizes osteosarcoma cells to bortezomib treatment via down-regulating PSMB5.","date":"2024","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/38252234","citation_count":1,"is_preprint":false},{"pmid":"41305476","id":"PMC_41305476","title":"HBV Infection Drives PSMB5-Dependent Proteasomal Activation in Humanized Mice and HBV-Associated HCC.","date":"2025","source":"Viruses","url":"https://pubmed.ncbi.nlm.nih.gov/41305476","citation_count":1,"is_preprint":false},{"pmid":"20968039","id":"PMC_20968039","title":"[Expression of proteasome subunits PSMB5 and PSMB9 mRNA in hippocampal neurons in experimental diabetes mellitus: link with apoptosis and necrosis].","date":"2010","source":"Fiziolohichnyi zhurnal (Kiev, Ukraine : 1994)","url":"https://pubmed.ncbi.nlm.nih.gov/20968039","citation_count":1,"is_preprint":false},{"pmid":"41409300","id":"PMC_41409300","title":"Targeting PSMB5-induced PANoptosis in bladder cancer: multi-omics insights and TCM candidate discovery.","date":"2025","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/41409300","citation_count":0,"is_preprint":false},{"pmid":"34187104","id":"PMC_34187104","title":"1,4-dihydropyridine derivatives increase mRNA expression of Psma3, Psmb5, and Psmc6 in rats.","date":"2021","source":"Arhiv za higijenu rada i toksikologiju","url":"https://pubmed.ncbi.nlm.nih.gov/34187104","citation_count":0,"is_preprint":false},{"pmid":"41826420","id":"PMC_41826420","title":"METTL16 enhances proteasome inhibitor resistance in multiple myeloma by inhibiting eIF2α-PERK interaction and promoting PSMB5 translation.","date":"2026","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/41826420","citation_count":0,"is_preprint":false},{"pmid":"41839959","id":"PMC_41839959","title":"VS-4718 enhances apoptosis induced by low-dose carfilzomib and overcomes carfilzomib resistance in PSMB5-mutated proteasome inhibitor resistant multiple myeloma.","date":"2026","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/41839959","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2024.10.17.618893","title":"Altered Proteasome Composition in Aging Brains, Genetic Proteasome Augmentation Mitigates Age-Related Cognitive Declines, and Acute Proteasome Agonist Treatment Rescues Age-Related Cognitive Deficits in Mice","date":"2024-10-20","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.17.618893","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":24599,"output_tokens":5951,"usd":0.081531,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14409,"output_tokens":4347,"usd":0.09036,"stage2_stop_reason":"end_turn"},"total_usd":0.171891,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2008,\n      \"finding\": \"An Ala49Thr mutation in the bortezomib-binding pocket of PSMB5 confers bortezomib resistance; siRNA-mediated silencing of PSMB5 restored bortezomib sensitivity in resistant cells, confirming PSMB5 as the direct target of bortezomib.\",\n      \"method\": \"Stepwise drug selection, cDNA sequencing, siRNA knockdown, chymotrypsin-like proteasome activity assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal functional rescue by siRNA, active-site mutation identified, replicated in multiple resistant lines\",\n      \"pmids\": [\"18565852\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"PSMB5 gene amplification (demonstrated by FISH/ISH) and mRNA overexpression correlate with increased chymotrypsin-like proteasome activity and bortezomib resistance in Jurkat-derived cells.\",\n      \"method\": \"Quantitative RT-PCR, FISH, in situ hybridization, fluorometric chymotrypsin-like activity assay, Western blot\",\n      \"journal\": \"Experimental hematology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (FISH, RT-PCR, activity assay) in a single lab\",\n      \"pmids\": [\"18562081\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Different point mutations in the PSMB5 bortezomib-binding pocket (Ala49Thr, Ala49Val, Ala49Thr+Ala50Val) confer graded levels of bortezomib resistance, with the double mutant conferring the highest resistance and the weakest inhibition of chymotrypsin-like activity by bortezomib.\",\n      \"method\": \"cDNA sequencing, limited dilution cloning, quantitative RT-PCR, fluorometric chymotrypsin-like activity assay, cytotoxicity assay\",\n      \"journal\": \"Experimental hematology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — active-site mutagenesis (natural variants) with dose-response and enzymatic activity readouts across multiple clones\",\n      \"pmids\": [\"19426847\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"A G322A point mutation in PSMB5 reduces accumulation of polyubiquitinated proteins and prevents bortezomib-induced ER stress (CHOP upregulation) and apoptosis; transfection of mutant PSMB5 into parental cells recapitulated resistance, confirming the mutation as sufficient for resistance.\",\n      \"method\": \"Sequencing, transfection with wild-type vs. mutant PSMB5, Western blot for ubiquitinated proteins/CHOP/caspase, apoptosis assay\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — gain-of-function transfection with mutant vs. wild-type PSMB5 plus orthogonal mechanistic readouts (ER stress, apoptosis markers)\",\n      \"pmids\": [\"20555361\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"PSMB5 gene transcription is induced by the bifunctional enzyme inducer 3-methylcholanthrene through the Nrf2-ARE pathway (not the AhR/Arnt-XRE pathway); mutation of proximal AREs in the Psmb5 promoter largely abolished inducibility, and 3-MC failed to induce PSMB5 in nrf2-null cells.\",\n      \"method\": \"Luciferase reporter assay with promoter deletion/mutation constructs, Nrf2 knockout cells, nuclear Nrf2 detection, proteasome activity assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — promoter mutagenesis, genetic KO of Nrf2, and activity assays with multiple orthogonal methods\",\n      \"pmids\": [\"16723119\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"PSMB5 mutations confer cross-resistance to second-generation proteasome inhibitors carfilzomib, ONX0912, and ONX0914, with the degree of cross-resistance depending on the specific mutation; P-glycoprotein overexpression also reduces chymotrypsin-like proteasome activity inhibition by these agents.\",\n      \"method\": \"Cytotoxicity assays, chymotrypsin-like activity assay in resistant cell lines with defined PSMB5 mutations\",\n      \"journal\": \"The Journal of pharmacology and experimental therapeutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetically defined PSMB5 mutant cell lines, multiple PI cross-resistance panel, single lab\",\n      \"pmids\": [\"22235146\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"STAT3 directly regulates PSMB5 promoter activity and protein expression; constitutively active STAT3 induces PSMB5 promoter and protein levels, while STAT3 knockdown or inhibition of STAT3 tyrosine phosphorylation coordinately reduces PSMB5 mRNA and protein and decreases chymotrypsin-like proteasome activity.\",\n      \"method\": \"STAT3 knockdown/inhibition, constitutively active STAT3 overexpression, PSMB5 promoter reporter assay, Western blot, proteasome activity assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — promoter reporter assay, gain- and loss-of-function STAT3 experiments, multiple orthogonal readouts in a single rigorous study\",\n      \"pmids\": [\"24627483\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"PSMB5 overexpression restores 20S proteasome activity in senescent human bone marrow stromal cells (hBMSCs), promotes cell proliferation (possibly via upregulation of Cyclin D1/CDK4), and enhances resistance to oxidative stress; PSMB5 knockdown in early-stage cells phenocopies senescence.\",\n      \"method\": \"Lentiviral overexpression/knockdown, proteasome activity assay, BrdU proliferation assay, Western blot, neural differentiation assay, H2O2 stress survival assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal gain/loss-of-function with multiple functional readouts, single lab\",\n      \"pmids\": [\"24393841\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Inhibition of Gα12/13 signaling decreases PSMB5 mRNA and protein expression and reduces chymotrypsin-like proteasome activity, thereby enhancing bortezomib cytotoxicity; conversely, constitutively active Gα12QL or Gα13QL increases PSMB5 expression and confers bortezomib resistance.\",\n      \"method\": \"Minigene-mediated G protein inhibition, constitutively active mutant overexpression, real-time PCR, Western blot, proteasome activity assay, cytotoxicity assay\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal gain/loss-of-function for Gα12/13, confirmed with activity and expression readouts, single lab\",\n      \"pmids\": [\"20478922\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"20-HETE regulates PSMB5 expression through the TGF-β/Smad3 signaling pathway: Smad3 directly binds the Smad binding element (SBE) in the PSMB5 promoter, as demonstrated by EMSA and luciferase assays; TGF-β receptor I kinase inhibitor SB431542 reversed 20-HETE-induced changes in PSMB5.\",\n      \"method\": \"Luciferase reporter assay, EMSA, TGF-β receptor inhibitor treatment, Western blot for Smad3 phosphorylation in transgenic mice\",\n      \"journal\": \"Prostaglandins & other lipid mediators\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — EMSA and promoter reporter assay showing direct Smad3 binding, pharmacological rescue, single lab\",\n      \"pmids\": [\"28807746\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PSMB5 is a direct target of miR-127-3p; overexpression of miR-127-3p reduces PSMB5 protein levels and inhibits prostate cancer cell invasion and migration in vitro. CTCF transcriptionally represses miR-127-3p by binding its promoter, thereby indirectly maintaining PSMB5 expression.\",\n      \"method\": \"miR-127-3p overexpression, luciferase reporter assay (3'UTR targeting), CTCF ChIP/promoter binding assay, invasion/migration assays\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct 3'UTR targeting validated, ChIP for CTCF, functional migration assays, single lab\",\n      \"pmids\": [\"31562641\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Ilexgenin A (IA) increases PSMB5 expression in an Nrf2-dependent manner; Nrf2 knockdown eliminates IA-induced PSMB5 upregulation and abolishes inhibition of Drp1 expression and mitochondrial fission, placing PSMB5 downstream of Nrf2 in mediating proteasomal degradation of Drp1.\",\n      \"method\": \"Nrf2 siRNA knockdown, Western blot for PSMB5/Drp1, proteasome inhibitor (epoxomicin) rescue experiment, mitochondrial morphology assessment\",\n      \"journal\": \"Drug development research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis (Nrf2 KD rescues PSMB5 induction), proteasome inhibitor rescue, multiple readouts, single lab\",\n      \"pmids\": [\"30762899\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Curcumin reduces PSMB5 protein levels by elevating miR-142-3p (which directly targets PSMB5 3'UTR), and this reduction is mediated through suppression of histone acetyltransferase p300, which normally inhibits miR-142-3p expression; loss of PSMB5 reduces chymotrypsin-like activity of the 20S proteasome.\",\n      \"method\": \"miR-142-3p overexpression/inhibition, luciferase 3'UTR reporter assay, p300 overexpression, proteasome activity assay, xenograft model, Western blot, qRT-PCR\",\n      \"journal\": \"Phytomedicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct 3'UTR targeting validated, gain/loss-of-function for p300 and miR-142-3p, in vivo confirmation, single lab\",\n      \"pmids\": [\"32866906\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Activation of PSMB5 (chymotrypsin-like proteasome activity) is required for EGCG-induced upregulation of Nmnat2 protein and subsequent SIRT6 activation; PSMB5 inhibition abolished EGCG-induced Nmnat2 protein expression and the anti-hypertrophic effect.\",\n      \"method\": \"PSMB5 pharmacological inhibition, Nmnat2 knockdown, luciferase reporter assay, EMSA for NF-κB, fluorometric SIRT6 activity assay, Western blot\",\n      \"journal\": \"Acta physiologica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological inhibition of PSMB5 with functional epistasis, multiple downstream readouts, single lab\",\n      \"pmids\": [\"33315278\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"rHMGB1 promotes mitochondrial fusion in endothelial cells via CXCR4/PSMB5-mediated Drp1 proteolysis; inhibition of CXCR4 reversed Drp1 downregulation, and inhibition of PSMB5 (but not NRF2 silencing) abolished rHMGB1-induced Drp1 downregulation and mitochondrial fusion, placing PSMB5 downstream of CXCR4 in this pathway.\",\n      \"method\": \"Specific receptor/PSMB5 inhibitors, siRNA for NRF2, Western blot for Drp1/PSMB5, confocal and TEM for mitochondrial morphology\",\n      \"journal\": \"Oxidative medicine and cellular longevity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological and genetic epistasis experiments, multiple orthogonal readouts, single lab\",\n      \"pmids\": [\"34394840\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ISG20L2 directly binds bortezomib and competes with PSMB5 for bortezomib binding, thereby attenuating bortezomib-induced inhibition of PSMB5 proteasome activity and conferring resistance; direct binding of bortezomib to ISG20L2 was confirmed by surface plasmon resonance.\",\n      \"method\": \"Biotinylated bortezomib pull-down assay, surface plasmon resonance, gain/loss-of-function studies, proteasome activity assay, in vivo xenograft\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct binding confirmed by SPR and biotinylated pull-down, gain/loss-of-function, in vivo validation, multiple orthogonal methods\",\n      \"pmids\": [\"36040812\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Knockdown of PSMB5 (Prosbeta5) suppressed CGG repeat-associated neurodegeneration in a Drosophila FXTAS model and in N2A cells via both RAN translation and RNA-mediated toxicity mechanisms.\",\n      \"method\": \"Drosophila genetic screen, PSMB5 knockdown in Drosophila and N2A cells, neurodegeneration assays, RAN translation assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockdown in two model systems with defined mechanistic readouts (RAN translation, RNA toxicity), single lab\",\n      \"pmids\": [\"35617426\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"The transcription factor THAP1 directly regulates PSMB5 gene expression; loss of THAP1 reduces PSMB5 levels, disrupts proteasome assembly, reduces proteasome activity, and causes accumulation of ubiquitinated proteins and cell death; exogenous PSMB5 expression rescues toxicity from THAP1 loss.\",\n      \"method\": \"Genome-wide coessentiality analysis (DepMap), THAP1 knockdown/KO, PSMB5 rescue expression, RNA-seq, deep mutational scan of THAP1 variants, proteasome assembly assay, ubiquitinated protein accumulation assay\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — genetic rescue by PSMB5 re-expression, RNA-seq for transcriptional targets, deep mutational scan, multiple orthogonal mechanistic assays\",\n      \"pmids\": [\"39929834\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"THAP1 directly binds the PSMB5 gene and regulates its transcription; THAP1 depletion disrupts proteasome assembly and impairs proteasome activity via reduced PSMB5 expression; this identifies a regulatory mechanism for basal proteasome expression distinct from the Nrf1-mediated compensatory pathway.\",\n      \"method\": \"Genome-wide genetic screen, ChIP for THAP1 at PSMB5 locus, THAP1 knockdown, proteasome assembly assay, ubiquitinated protein accumulation assay\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — direct ChIP showing THAP1 binding PSMB5 locus, genetic screen, mechanistic epistasis, two independent concurrent papers\",\n      \"pmids\": [\"39952963\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Mitochondrial succinyl-CoA drives succinylation of BRD2, which impairs BRD2-dependent transcription of PSMB5; reduced PSMB5 expression leads to elevated Hobit protein levels (due to impaired proteasomal degradation) and promotes CD4+ Trm cell differentiation in rheumatoid arthritis.\",\n      \"method\": \"BRD2 identification by chromatin immunoprecipitation-qPCR, succinyl-CoA manipulation in T cells, THAP1 silencing, Trm differentiation assays, humanized NSG chimera model\",\n      \"journal\": \"Arthritis & rheumatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-qPCR validated BRD2-PSMB5 interaction, metabolic manipulation of succinyl-CoA, in vivo humanized model, single lab\",\n      \"pmids\": [\"39037181\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"IFN-γ stimulation causes replacement of the constitutively expressed PSMB5 subunit in the 20S proteasome by the inducible LMP7 (PSMB8) subunit; the mouse Psmb5 gene has a unique three-exon structure spanning ~5 kb, conserved with the human gene, and maps to chromosome 14 band C2–D1.\",\n      \"method\": \"Gene structure analysis, interspecific backcross mapping, fluorescent in situ hybridization (FISH)\",\n      \"journal\": \"Immunogenetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct FISH and genetic mapping, subunit replacement mechanism inferred from established literature supported by structural data\",\n      \"pmids\": [\"9382924\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"METTL16 promotes PSMB5 translation in an m6A methyltransferase activity-independent manner by inhibiting the eIF2α-PERK interaction and reducing eIF2α phosphorylation, thereby increasing PSMB5 protein levels, proteasome activity, and bortezomib resistance in multiple myeloma cells.\",\n      \"method\": \"METTL16 overexpression/knockdown, eIF2α phosphorylation analysis, polysome profiling/translational assay, proteasome activity assay, PI sensitivity assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic link via eIF2α-PERK interaction assay and translational control, gain/loss-of-function, single lab\",\n      \"pmids\": [\"41826420\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2030,\n      \"finding\": \"PSMB5 overexpression in neurons slows age-related decline in spatial learning/memory and neuromuscular function in mice, establishing that neuronal PSMB5-dependent proteasome activity is required for maintenance of cognitive function during aging.\",\n      \"method\": \"Transgenic PSMB5 neuron-specific overexpression in mice, spatial learning/memory behavioral assays, neuromuscular assessments, proteasome activity assays in aged brain\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 2 / Weak — preprint, single lab, behavioral phenotype with mechanistic link to proteasome activity but limited mechanistic detail in abstract\",\n      \"pmids\": [\"bio_10.1101_2024.10.17.618893\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"PSMB5 encodes the β5 (chymotrypsin-like) catalytic subunit of the 20S proteasome core; its expression is transcriptionally regulated by Nrf2 (via AREs), STAT3, THAP1 (direct promoter binding), TGF-β/Smad3, and Gα12/13 signaling, and post-transcriptionally by miR-142-3p and miR-127-3p; bortezomib binds directly within the PSMB5 active-site pocket, and mutations at Ala49/Ala50 or overexpression of PSMB5 confer graded resistance by reducing drug binding and preventing accumulation of ubiquitinated proteins/ER stress; ISG20L2 can compete with PSMB5 for bortezomib binding as an additional resistance mechanism; PSMB5 activity mediates proteasomal degradation of substrates such as Drp1 (regulating mitochondrial fission) and Hobit (regulating T cell differentiation), and neuronal PSMB5-dependent proteasome function is required for cognitive maintenance during aging.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"PSMB5 encodes the chymotrypsin-like catalytic subunit of the 20S proteasome core, and its activity sets the rate of proteasomal protein degradation [#0, #3]. Under IFN-γ stimulation the constitutive PSMB5 subunit is replaced by the inducible LMP7 (PSMB8) subunit during immunoproteasome formation [#20]. PSMB5 is the direct molecular target of bortezomib, which binds within its active-site pocket; point mutations at Ala49/Ala50 and gene amplification/overexpression confer graded drug resistance by reducing inhibitor binding and preventing the accumulation of polyubiquitinated proteins and the resulting ER stress and apoptosis [#0, #2, #3], and these mutations cross-resist second-generation inhibitors carfilzomib, ONX0912, and ONX0914 [#5]. PSMB5 expression is controlled by a convergent set of regulators: the Nrf2-ARE pathway [#4, #11], STAT3 acting at the PSMB5 promoter [#6], TGF-β/Smad3 via a Smad-binding element [#9], Gα12/13 signaling [#8], and the transcription factor THAP1, which binds the PSMB5 locus to drive basal proteasome expression — THAP1 loss collapses proteasome assembly and activity in a manner rescued by exogenous PSMB5 [#17, #18]. Post-transcriptionally, PSMB5 is repressed by miR-142-3p and miR-127-3p targeting its 3'UTR [#10, #12] and translationally enhanced by METTL16 through suppression of eIF2α phosphorylation [#21]. Functionally, PSMB5-dependent degradation controls specific substrates including Drp1, linking proteasome activity to mitochondrial fission/fusion [#11, #14], and Hobit, regulating CD4+ tissue-resident memory T cell differentiation [#19]; PSMB5 activity also sustains proteostasis in cellular senescence and oxidative-stress resistance [#7].\"\n  ,\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Established PSMB5 as the constitutive catalytic subunit whose place in the 20S core is exchangeable, defining the substitution by inducible LMP7 that switches proteasome specificity upon immune stimulation.\",\n      \"evidence\": \"Gene structure analysis, interspecific backcross mapping, and FISH in mouse\",\n      \"pmids\": [\"9382924\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Subunit replacement was inferred rather than directly reconstituted\", \"No catalytic mechanism or substrate spectrum addressed\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identified the first upstream transcriptional control of PSMB5, showing inducer-driven expression runs through the Nrf2-ARE pathway rather than AhR/XRE signaling.\",\n      \"evidence\": \"Promoter deletion/mutation luciferase reporters, Nrf2-null cells, and proteasome activity assays\",\n      \"pmids\": [\"16723119\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not link Nrf2-driven PSMB5 levels to specific degradation substrates\", \"Other constitutive regulators not surveyed\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Demonstrated that PSMB5 is the direct pharmacological target of bortezomib and that an active-site Ala49 mutation suffices for resistance, settling the drug's mechanism of action.\",\n      \"evidence\": \"Stepwise drug selection, cDNA sequencing, siRNA rescue, and chymotrypsin-like activity assays; FISH/RT-PCR for amplification\",\n      \"pmids\": [\"18565852\", \"18562081\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of altered drug binding not resolved at atomic level\", \"Did not establish whether amplification arises clinically\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Showed mutant PSMB5 is sufficient to confer resistance by blocking polyubiquitinated protein accumulation and downstream ER stress/apoptosis, and that Gα12/13 signaling tunes PSMB5 levels and bortezomib sensitivity.\",\n      \"evidence\": \"Mutant vs. wild-type PSMB5 transfection with CHOP/caspase Western blots; Gα12/13 minigene inhibition and constitutively active mutants\",\n      \"pmids\": [\"20555361\", \"20478922\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The downstream effectors connecting Gα12/13 to the PSMB5 promoter were not mapped\", \"ER stress link is correlative with activity, not substrate-specific\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Defined that PSMB5 active-site mutations produce graded, mutation-specific cross-resistance to second-generation proteasome inhibitors, generalizing the resistance mechanism beyond bortezomib.\",\n      \"evidence\": \"Cytotoxicity and chymotrypsin-like activity assays in genetically defined PSMB5 mutant lines across an inhibitor panel\",\n      \"pmids\": [\"22235146\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"P-glycoprotein contribution not separated from PSMB5 mutation effects\", \"Single-lab cell-line panel\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Expanded the transcriptional control map by establishing STAT3 as a direct PSMB5 promoter regulator and linked PSMB5 levels to proteostatic maintenance against senescence and oxidative stress.\",\n      \"evidence\": \"STAT3 gain/loss-of-function with promoter reporters; lentiviral PSMB5 overexpression/knockdown in hBMSCs with proliferation, differentiation, and H2O2 survival assays\",\n      \"pmids\": [\"24627483\", \"24393841\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cyclin D1/CDK4 link to proliferation remains correlative\", \"Senescence phenotype mechanism not tied to specific substrates\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Added TGF-β/Smad3 as a direct PSMB5 promoter input via a Smad-binding element, connecting lipid-mediator (20-HETE) signaling to proteasome subunit expression.\",\n      \"evidence\": \"Luciferase reporters, EMSA showing direct Smad3 binding, and TGF-β receptor inhibitor rescue in transgenic mice\",\n      \"pmids\": [\"28807746\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological consequence of altered PSMB5 in this context not defined\", \"Single-lab\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified post-transcriptional repression of PSMB5 by miR-127-3p and placed PSMB5 downstream of Nrf2 in driving proteasomal degradation of Drp1, linking it to mitochondrial fission control.\",\n      \"evidence\": \"miR-127-3p 3'UTR reporter and CTCF ChIP; Nrf2 siRNA epistasis with epoxomicin rescue and mitochondrial morphology readouts\",\n      \"pmids\": [\"31562641\", \"30762899\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct PSMB5-mediated cleavage of Drp1 not shown biochemically\", \"Single-lab for each axis\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Established miR-142-3p as a second direct PSMB5-repressing microRNA controlled by p300, and that lowering PSMB5 reduces 20S chymotrypsin-like activity, validated in vivo.\",\n      \"evidence\": \"miR-142-3p 3'UTR reporter, p300 gain/loss-of-function, proteasome activity assays, and xenografts\",\n      \"pmids\": [\"32866906\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative contribution of multiple miRNAs to physiological PSMB5 not weighed\", \"Single-lab\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Implicated PSMB5 proteasome activity in additional signaling outputs — Nmnat2/SIRT6 activation and CXCR4-driven Drp1 proteolysis governing mitochondrial fusion.\",\n      \"evidence\": \"Pharmacological PSMB5 inhibition with downstream Nmnat2/SIRT6 readouts; receptor/PSMB5 inhibitors and NRF2 siRNA with mitochondrial imaging\",\n      \"pmids\": [\"33315278\", \"34394840\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Effects rely on pharmacological inhibition that affects whole 20S activity, not PSMB5 selectively\", \"Direct substrate engagement not shown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Revealed a non-mutational resistance mechanism in which ISG20L2 directly binds bortezomib and competes for the drug, sparing PSMB5 activity; also showed PSMB5 knockdown suppresses CGG-repeat neurodegeneration.\",\n      \"evidence\": \"Biotinylated bortezomib pull-down and SPR for ISG20L2 binding with in vivo validation; Drosophila/N2A FXTAS models with RAN translation assays\",\n      \"pmids\": [\"36040812\", \"35617426\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How ISG20L2 expression is regulated in resistant patients unaddressed\", \"FXTAS protective mechanism via PSMB5 not mechanistically resolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Connected mitochondrial metabolism to PSMB5 expression and immune cell fate: succinylation of BRD2 impairs PSMB5 transcription, raising Hobit and driving CD4+ Trm differentiation.\",\n      \"evidence\": \"ChIP-qPCR for BRD2 at PSMB5, succinyl-CoA manipulation, and humanized NSG chimera Trm assays\",\n      \"pmids\": [\"39037181\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct PSMB5-mediated degradation of Hobit not biochemically demonstrated\", \"Single-lab\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identified THAP1 as a direct transcriptional driver of basal PSMB5 expression and proteasome assembly, distinct from Nrf1 compensation, with METTL16 providing parallel translational enhancement.\",\n      \"evidence\": \"DepMap coessentiality, THAP1 ChIP at PSMB5, PSMB5 rescue of THAP1-loss toxicity, deep mutational scan; METTL16 gain/loss with eIF2α/polysome assays\",\n      \"pmids\": [\"39929834\", \"39952963\", \"41826420\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relationship between THAP1-driven PSMB5 control and dystonia phenotypes not addressed\", \"METTL16's m6A-independent mechanism mechanistically incomplete\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Whether neuronal PSMB5-dependent proteasome activity is causally required for cognitive maintenance during aging remains to be established in peer-reviewed work.\",\n      \"evidence\": \"Transgenic neuron-specific PSMB5 overexpression with behavioral and proteasome activity assays (preprint)\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Preprint, single lab, limited mechanistic detail\", \"No identified neuronal substrate linking PSMB5 to cognition\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 3]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 2, 3]}\n    ],\n    \"localization\": [],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [0, 3, 17]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [20]}\n    ],\n    \"complexes\": [\"20S proteasome\", \"immunoproteasome\"],\n    \"partners\": [\"PSMB8\", \"ISG20L2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":6,"faith_total":6,"faith_pct":100.0}}